PD-L1-IN-3 

PD-L1-IN-3 (Compound 4a) is a compound that targets PD-1/PD-L1, the IC₅₀ value and EC₅₀ value is 4.97nM and 2.70 μM for inhibit PD-L1 and Jurkat T cells, respectively. PD-L1-IN-3 can bind PD-L1 dimer to prevent PD-1 binding to PD-L1, therefore blocking PD-1 signaling. PD-L1-IN-3 can be used for lung cancer and melanoma diseases research^[1].

PD-L1-IN-3 (Compound 4a) (0.01-100 μM, 40 min) disrupts the binding between PD-1 and PD-L1 and enhances a TCR-mediated activation of the Jurkat cells^[1].
PD-L1-IN-3 (0.01-100 μM, 40 min) has higher uptake which correlated with PD-L1 expression in PD-L1⁺ H358 tumors^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

374.86

C₁₉H₁₆ClFN₂OS

2953044-29-4

FC1=CC=C(C2=CSC(OCC3=CC=C(CN)C=C3)=C2C#N)C=C1.Cl

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Ważyńska MA, et al. Design, Synthesis, and Biological Evaluation of 2-Hydroxy-4-phenylthiophene-3-carbonitrile as PD-L1 Antagonist and Its Comparison to Available Small Molecular PD-L1 Inhibitors. J Med Chem. 2023 Jul 27;66(14):9577-9591.  [Content Brief]